

THE #1 PRESCRIBED AID SYSTEM*

OMNIPOD[®] 5

COMPATIBLE WITH
Dexcom G6 and G7

Omnipod 5 simplifies insulin management to make diabetes a smaller part of your patient's day—and an easier part of yours.



Pod, Dexcom G6 and Dexcom G7 shown without the necessary adhesive.



SIMPLE FOR YOU

Omnipod 5 is always adjusting, so you don't have to. SmartAdjust™ technology is built into each Pod that proactively helps to correct highs and helps to protect from lows.¹⁻³

SIMPLE FOR THEM

More sensor options make it easier for patients to start using Omnipod 5 today.

SIMPLE TO ACCESS

Omnipod 5 has over 90% coverage, representing over 300 million covered lives.*

*USA 2023, Data on file.

1. Brown S, et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Mean time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.9% vs. 1.3%, P<0.0001; 2.2% vs. 1.8%, P=0.8153, respectively. Results measured by CGM. Study funded by Insulet.
2. Sherr JL, et al. Diabetes Care. 2022. 45(8):1907-1910. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL in very young children (2 - 5.9 yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.43%, 3-mo Omnipod 5 = 2.46%, P=0.0204. Results measured by CGM. Study funded by Insulet.
3. Pasquel FJ, et al. Presented at: ADA; June 21-24, 2024; Orlando, FL. Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL as measured by CGM: ST = 54%, 3-mo Omnipod 5 = 34%, P<0.001. Mean time <70 mg/dL as measured by CGM: ST = 0.2%, 3-mo Omnipod 5 = 0.2%.

* Reflects coverage for Omnipod 5 G6 Intro Kit and Omnipod 5 G6 Pods. Source: Insulet Data on File As of June 1 2023.

Compatible with
Dexcom

How to prescribe

Omnipod® 5 with Dexcom G6 and G7

For your patients on multiple daily injections or a tubed pump, prescribe Omnipod 5 with Dexcom through ASPN or your patients preferred pharmacy

e-prescribe

- 1 For new to Omnipod 5 patients, send both Intro Kit and refill pods to ASPN or your patients preferred pharmacy.
- 2 For your existing Omnipod 5 patients, send a prescription for refill pods to your patients preferred pharmacy.

Customers with insurance plans requiring local pickup will be unable to be processed by ASPN (including Medicaid insured customers). Please contact customer care for assistance.

Rx details

Product description	Package contents	Quantity	Refills	Dosing/Rx SIG instructions
Omnipod 5 DexG7G6 Intro Kit (Gen 5) OR Omnipod 5 G6 Intro Kit (Gen 5) NDC: 08508-3000-01	Controller and 10 Pods	1 Kit	None	Change Pod every 72 or 48 hrs* Based on total daily insulin usage
Omnipod 5 DexG7G6 Pods (Gen 5) OR Omnipod 5 G6 Pods (Gen 5) NDC: 08508-3000-21	5 Pods per box	2 boxes	1 year Monthly fills	Change Pod every 72 or 48 hrs* Based on total daily insulin usage

*If patient requires a 48-hour Pod change frequency, quantity should be 3 boxes. Clinical rationale must be provided for 48-hour Pod changes.



Pod, Dexcom G6 and Dexcom G7 shown without the necessary adhesive.

Insulet | 100 Nagog Park, Acton, MA 01720 | 1-800-591-3455
omnipod.com



dexcom

aspn Pharmacies

Important Safety Information: The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes in persons 18 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoRapid®, Humalog®, and Admelog®. Refer to the Omnipod 5 Automated Insulin Delivery System User Guide at omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions.

© 2024 Insulet Corporation. Omnipod, the Omnipod 5 logo, and SmartAdjust are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. Dexcom, Dexcom G6 and Dexcom G7 are registered trademarks of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation. INS-OHS-10-2024-00092 v1.0